Annonce

Log ud Log ind
Log ud Log ind
Formue

Q3 webcast: Se Ambus ledelse i Q&A med analytikere

Frederik Lorenzen

tirsdag 22. september 2020 kl. 12:23

Efter aflæggelse af Q3 regnskabet afholdte Ambus ledelse med analytikerne, deres investorpræsentation som kan ses via dette link. Her har man mulighed for at høre Q&A med analytikerne efter ledelsens indledende præsentation.

Ambu indleder præsentationen sådan:

 Highlights Q3 2020:

  • For Q3, revenue totaled DKK 947m (vs. DKK 773m LY), equal to 23% reported growth. Year-to-date reported growth was 22%. Organic growth for Q3 and year to date was 21% and 20%, respectively.
  • EBIT before special items for the quarter was DKK 156m (DKK 155m) with an EBIT margin before special items of 16.5% (20.1%), while EBIT before special items year to date was DKK 399m (DKK 462m) equating to an EBIT margin before special items of 14.8% (20.9%).
  • In Q3, Visualization achieved organic growth of 81%, Anaesthesia declined by -1%, and Patient Monitoring & Diagnostics (PMD) declined by -32%. Year to date, Visualization grew 60% organically, Anaesthesia 3% while PMD was negative by -10%. Organic growth is driven by a high demand for bronchoscopes and resuscitators, with geographical variations, but negatively impacted by other products within Anaesthesia and PMD that are used for elective procedures.
  • For the quarter, North America declined -10%, while Europe grew 59% and Rest of World grew 31%. Year to date, North America grew 7%, Europe 38% and Rest of World 15%. The negative growth in North America was mainly ascribable to Anaesthesia and PMD, which declined -18%.
  • Sales of single-use endoscopes reached 337,000 units for the quarter and 830,000 units year to date. Sales volumes were thus up 74% and 58%, respectively, relative to last year.
  • The aScope™ Duodeno has been granted designation as a breakthrough device by the FDA and received 510(k) clearance on 17 July 2020. This is our third launch of the year in single-use endoscopy and shows Ambu’s ability to develop and bring to market advanced single-use endoscopy solutions.
  • Following the FDA clearance of our aScope™ Duodeno, we have conducted several product demonstrations in the U.S. with positive feedback from physicians. We are also building deep expertise within the field of gastrointestinal (GI) endoscopy on the back of creating our GI commercial organization in the U.S. In terms of our clinical study, the plan was to start 1 September 2020. However, as the COVID-19 recovery is taking longer than expected, hospital administrations have been unable to confirm the start date of our clinical study, and we therefore expect this to commence later than initially planned.
  • Travel restrictions and delays from suppliers caused by the COVID-19 pandemic have impacted the launch of our colonoscope and gastroscope that was planned to be launched in Q2 2020/21 and which we now expect to launch in H2 2020/21.
  • Gross margin for the quarter was 64.7% (56.4%). The comparison with last year should be adjusted for the effect of inventory write-downs following the discontinuation of the SC210 colonoscope in Q3 2018/19. Adjusted for this effect, the gross margin increased by approx. 5 percentage points. The gross margin year to date was 62.2% (58.8%).
  • Capacity costs for the quarter totaled DKK 457m (DKK 281m), corresponding to an increase of 63% for the quarter and 52% year to date. Capacity costs are increasing primarily due to the investments in commercial infrastructure announced in June and August 2019 and in May 2020. Our commercial expansion is progressing as planned and is as previously announced expected to be fully completed by the end of Q1 2020/21.
  • Net working capital to revenue ratio was 17% (21%) by the end of the quarter based on rolling 12-month revenue. Our supply chain has been significantly impacted by the strong increase in demand caused by the pandemic, and for certain product categories our global inventories are lower than what we would like them to be in the longer term.
  • Free cash flow before acquisitions totaled DKK 187m (DKK 148m) for the quarter and was negative year to date at DKK -92m (DKK +204m), which is in line with our investment plan. The EUR 40m milestone payment associated with FDA clearance of the duodenoscope falls due in Q1 2020/21.
  • The organic growth for the 2019/20 financial year is now expected to be ‘approx. 26%’ compared to previously ‘26-30%’ as the impact of COVID-19 has been more protracted than expected, especially in the U.S. This impacts volume of elective procedures and the revenue contribution from our Anaesthesia and PMD portfolios. As a result, we now expect growth for our Anaesthesia and PMD portfolios to be slightly negative for the full year 2019/20. Our full-year expectations for Visualization are unchanged, and we still expect to sell more than 1 million endoscopes in 2019/20. As a result of the lower growth for the full year, our expectations for EBIT margin before special items are reduced from ‘12-14%’ to now ‘approx. 12%’. The outlook for the 2019/20 financial year is therefore:
    • Organic growth of approx. 26%.
    • EBIT margin before special items of approx. 12%.
    • Sales of more than 1 million endoscope units (unchanged compared to previously announced outlook).
Tilmeld dig vores gratis nyhedsbrev
ØU Top100 Finansvirksomhed

Få de vigtigste om bank, realkredit, forsikring, pension
Udkommer hver mandag.

Jeg giver samtykke til, at I sender mig mails med de seneste historier fra Økonomisk Ugebrev. Lejlighedsvis må I gerne sende mig gode tilbud og information om events. Samtidig accepterer jeg ØU’s Privatlivspolitik.

Du kan til enhver tid afmelde dig med et enkelt klik.

[postviewcount]

Jobannoncer

Grønborg: Bankernes rejse nærmer sig afslutningen
Udløber snart
Forretningsudvikler til Pension og Formue
Pension, Formue
Aabenraa
Grønborg: Bankernes rejse nærmer sig afslutningen
Udløber snart
Formuerådgiver
Formuerådgiver
Midt- og Nordjylland
Grønborg: Bankernes rejse nærmer sig afslutningen
Udløber snart
Afdelingsdirektør for forretningsudvikling Private Banking
Private Banking
Aabenraa
Grønborg: Bankernes rejse nærmer sig afslutningen
Udløber snart
Formuerådgiver
Formuerådgiver
Region hovedstaden og Sjælland
Regnskabsassistent til Pharma Nord
Region Syddanmark
Generalsekretær i Folkekirkens Nødhjælp
Region Hovedstaden
ØKONOMIMEDARBEJDER – Carlsbergfondet
Region Hovedstaden
DIGITALISERINGSCHEF – Muskelsvindfonden
Region H
Direktionskonsulent med flair for økonomi og udviklingsprojekter
Region Sjælland
Kontorchef for økonomi, analyse og kunder i Færdselsstyrelsen
Region H

Mere fra ØU Formue

Log ind

Har du ikke allerede en bruger? Opret dig her.

FÅ VORES STORE NYTÅRSUDGAVE AF FORMUE

Her er de 10 bedste aktier i 2022

Tilbuddet udløber om:
dage
timer
min.
sek.

Analyse af og prognoser for Fixed Income (statsrenter og realkreditrenter)

Direkte adgang til opdaterede analyser fra toneangivende finanshuse:

Goldman Sachs

Fidelity

Danske Bank

Morgan Stanley

ABN Amro

Jyske Bank

UBS

SEB

Natixis

Handelsbanken

Merril Lynch 

Direkte adgang til realkreditinstitutternes renteprognoser:

Nykredit

Realkredit Danmark

Nordea

Analyse og prognoser for kort rente, samt for centralbankernes politikker

Links:

RBC

Capital Economics

Yardeni – Central Bank Balance Sheet 

Investing.com: FED Watch Monitor Tool

Nordea

Scotiabank